Literature DB >> 23331007

Glioblastoma tumor initiating cells: therapeutic strategies targeting apoptosis and microRNA pathways.

J Liu1, A M Albrecht, X Ni, J Yang, M Li.   

Abstract

Glioblastoma (GBM) is a highly malignant primary brain tumor known for its invasiveness and aggressive resistance to standard treatment. It is currently the most common primary brain tumor which is associated with a high mortality rate. Tumor initiating cells (TICs) are a subpopulation of GBM stem cells which are capable of self-renewal and apoptotic resistance, and are thought to account for GBMs aggressive nature. Recent efforts have focused on therapies which target key intracellular apoptotic pathways which may confer tumor resistance, such as Akt, p53, Bcl-2 family proteins, caspase family proteases, and more recently microRNAs. Research into microRNA's role in GBM has shown that microRNAs play a key regulatory role in the GBM apoptotic pathway, making it a potential therapeutic target. In this review we summarized the molecular mechanisms involved in the signaling pathways of human GBM TIC apoptosis and microRNAs, the contemporary treatments involving different members of the signaling cascade, and the future direction of GBM treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23331007

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  18 in total

Review 1.  Cancer stem cells: a systems biology view of their role in prognosis and therapy.

Authors:  Susan D Mertins
Journal:  Anticancer Drugs       Date:  2014-04       Impact factor: 2.248

2.  The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.

Authors:  Yinxing Liu; Misty R Gilbert; Natasha Kyprianou; Vivek M Rangnekar; Craig Horbinski
Journal:  Acta Neuropathol       Date:  2014-08-19       Impact factor: 17.088

Review 3.  Toward Personalized Targeted Therapeutics: An Overview.

Authors:  Shiao-Pei S Weathers; Mark R Gilbert
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 4.  Resistance to Cell Death and Its Modulation in Cancer Stem Cells.

Authors:  Ahmad R Safa
Journal:  Crit Rev Oncog       Date:  2016

5.  Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells.

Authors:  Mercedes Martín-Rufián; Renata Nascimento-Gomes; Ana Higuero; Amanda R Crisma; José A Campos-Sandoval; María C Gómez-García; Carolina Cardona; Tzuling Cheng; Carolina Lobo; Juan A Segura; Francisco J Alonso; Monika Szeliga; Jan Albrecht; Rui Curi; Javier Márquez; Alison Colquhoun; Ralph J Deberardinis; José M Matés
Journal:  J Mol Med (Berl)       Date:  2013-11-26       Impact factor: 4.599

6.  Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs.

Authors:  Ahmad R Safa; Mohammad Reza Saadatzadeh; Aaron A Cohen-Gadol; Karen E Pollok; Khadijeh Bijangi-Vishehsaraei
Journal:  Genes Dis       Date:  2015-06

7.  Enhancing Cancer Drug Discovery through Novel Cell Signaling Pathway Panel Strategy.

Authors:  Liang Schweizer; Litao Zhang
Journal:  Cancer Growth Metastasis       Date:  2013-08-20

8.  MicroRNA-382 induced by HIF-1α is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog.

Authors:  Jin-Kyung Seok; Sun Hee Lee; Min Jung Kim; You-Mie Lee
Journal:  Nucleic Acids Res       Date:  2014-06-09       Impact factor: 16.971

9.  Emerging targets for glioblastoma stem cell therapy.

Authors:  Ahmad R Safa; Mohammad Reza Saadatzadeh; Aaron A Cohen-Gadol; Karen E Pollok; Khadijeh Bijangi-Vishehsaraei
Journal:  J Biomed Res       Date:  2015-09-20

10.  RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop.

Authors:  Nis David Giladi; Amotz Ziv-Av; Hae Kyung Lee; Susan Finniss; Simona Cazacu; Cunli Xiang; Hiba Waldman Ben-Asher; Ana deCarvalho; Tom Mikkelsen; Laila Poisson; Chaya Brodie
Journal:  Oncotarget       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.